Silence Therapeutics PLC Silence Continued Expansion of IP (4723G)
May 30 2017 - 2:02AM
UK Regulatory
TIDMSLN
RNS Number : 4723G
Silence Therapeutics PLC
30 May 2017
Continued expansion of Intellectual Property - additional US
patent application allowed for grant
30 May 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces a further step in the expansion of its
chemical modification patent estate.
Earlier in May 2017, Silence announced that it had expanded and
strengthened its above patent estate by filing additional
divisional and continuation patent applications in Europe and the
US respectively. The Company also announces that subsequently the
US Patent Office issued a notice of allowance for US patent
application 14/977,710. Silence has made the relevant payment of
grant fees and normal practice is that the granted patent will now
be issued by the US Patent and Trade Mark Office
The allowed claims of US patent application 14/977,710 provide
Silence with further protection for its innovative chemical
modification technology in the US. We believe these allowed claims
are relevant to third party medicines in ongoing clinical trials
for conditions including, but not exclusively limited to,
Hypercholesterolemia, Haemophilia and Acute Hepatic Porphyrias.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics,
commented:
"In allowing this additional patent application for grant, the
US patent office has continued to uphold the validity of our
expanding US patent estate. We continue to believe that several
third party late-stage clinical RNAi candidates, including lipid
nanoparticle and GalNAc based products, require licences under our
patent portfolio, and have therefore written to one company to this
effect. Silence is committed to defending and securing the
appropriate value for our IP and is exploring alternative ways to
leverage this asset. The first launch for these medicines is
anticipated in 2018. We consider that potential licences under our
patent estate could have a significant financial effect relative to
the current market capitalisation of Silence."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Ali Mortazavi, Chief Executive Officer 6900
David Ellam, Chief Financial Officer
Canaccord Genuity Limited (Nominated Adviser Tel: +44 (0)20 7523
and Joint Broker) 8350
Henry Fitzgerald-O'Connor/Emma Gabriel
Peel Hunt LLP (Joint Broker) Tel: +44 (0)20 7418
James Steel/Oliver Jackson 8900
Media Enquiries: Tel: +44 (0) 20 3727
FTI Consulting 1000
Simon Conway/Brett Pollard/Stephanie Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSEAFAUFWSEFI
(END) Dow Jones Newswires
May 30, 2017 02:01 ET (06:01 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024